rafal_olechowski
- Centogene (NASDAQ:CNTG) recently announced the extension of its collaboration with Takeda
Pharmaceutical (NYSE:TAK) to provide diagnostic solutions for patients with Lysosomal Storage
Disorders (LSDs), a collection of inherited metabolic conditions. - Under the agreement, the German biotech company will continue to offer its testing services to Takeda
for the early and efficient diagnosis of patients with LSDs like Fabry disease, Gaucher disease, and
Hunter syndrome. - The significance of this renewed partnership with Takeda underscores the ongoing global necessity to expedite the diagnosis process for LSD patients, with CENTOGENE proving its crucial capability to deliver this essential service,” expressed Centogene’s commercial chief, Ian Rentsch.
- This announcement marks the latest iteration of a deal originally forged by CNTG back in 2015 with Shire Pharmaceuticals, a company acquired by the Japanese pharmaceutical giant for $62 billion in 2019.
